GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

Shalini Kumar has joined Kenvue as Head - Consumer Experience. Shalini was earlier with Halenon as Area Media Lead for ...

A total of 739 deals were completed so far this year representing a decrease of just under 21 per cent compared to last year.